Press Releases
- Nov 13, 2025NoviThera has initiated the first efficacy animal studiesRead More
- Oct 22, 2025Orocidin’s QR-01 Shows Positive Results in Treating Periodontitis in the treatment of experimental periodontitis in Wistar rats.Read More
- Oct 20, 2025Orocidin develops novel cGMP manufacturing process in collaboration with SyngeneRead More
- Oct 3, 2025Nordicus Partners Corporation Announces The Formation Of A New Company, NoviThera ApSRead More
- Sep 2, 2025Nordicus Partners Corporation Applies to Uplist to the Nasdaq Capital MarketRead More
- Aug 7, 2025Nordicus Partners Corporation Appoints Three New Members to Its Board of DirectorsRead More
- Apr 3, 2025Bio-Convert Receives Positive Feedback from The Danish Medicine Agency (DKMA) on its Lead Drug Candidate, QR-02 for Oral LeukoplakiaRead More
- Apr 2, 2025Orocidin’s QR-01 Shows Positive Results in Treating Periodontitis in DogsRead More
- Feb 20, 2025Orocidin and Syngene Partner to Accelerate Biotech InnovationRead More
- Feb 18, 2025Orocidin QR-01 Shows a Good Safety Profile in Preclinical Toxicity StudyRead More
- Feb 3, 2025Bio-Convert Develops QR-02, a Potential Breakthrough in the Treatment of Oral Leukoplakia Read More
- Jan 28, 2025Oricidin Launches Groundbreaking Dental Gel for Long-Term Periodontitis TreatmentRead More
- Jan 14, 2025Nordicus Partners Corporation Announces Key Milestone in Development of Orocidin’s Breakthrough Treatment for PeriodontitisRead More